Background/Aims: It is unclear whether tumor location, size, or the presence of multiple
endocrine neoplasia type 1 (MEN-1) alters metastatic rate and survival in patients with …

Background & Aims: Risk factors of metachronous liver metastases and death are not well
known in patients with the Zollinger–Ellison syndrome and multiple endocrine neoplasia …

PURPOSE: The long-term clinical course of unselected patients with gastrinomas as well as
other functional pancreatic endocrine tumors (PETs) in whom the excess-hormone state is …

The clinical evolution of type I multiple endocrine neoplasia (MEN I) was studied in 45
patients among a consecutive series of 172 with Zollinger-Ellison syndrome (ZES). These …

Objective To determine the role of surgery in patients with Zollinger-Ellison syndrome (ZES)
and multiple endocrine neoplasia type 1 (MEN1) with either limited or advanced pancreatic …

Objective: The authors assessed the impact of gastrinoma resection on the subsequent
development of hepatic metastases in Zollinger-Ellison syndrome. Summary Background …

BACKGROUND: Gastric carcinoid tumors occur in 15% to 50% of patients with multiple
endocrine neoplasia–1/Zollinger-Ellison syndrome (MEN-1/ZES) but are thought to be …

Pancreaticoduodenal tumors develop in a majority of patients with multiple endocrine
neoplasia type 1 (MEN 1) and have a pronounced effect on life expectancy as the principal …

The natural history of pancreatic endocrine tumors (PETs) in patients with MEN1 is largely
unknown. Recent studies in patients with sporadic PETs show that in a subset, tumor growth …

Objective: To determine whether routine use of duodenotomy (DUODX) alters cure rate,
survival, or development of liver metastases in 143 patients (162 operations) with Zollinger …